May 24, 2016
SAN FRANCISCO — Patients requiring single-chamber pacing experience fewer overall complications with a leadless pacemaker than with a transvenous pacemaker, according to data presented at the Heart Rhythm Society Annual Scientific Sessions.
Vivek Y. Red
, and colleagues compared acute and midterm adverse event rates of leadless pacemakers (Nanostim, St. Jude Medical) vs. transvenous pacemakers. Using data from the LEADLESS II clinical trial and Truven Health MarketScan databases, 718 patients with a leadless pacemaker and 10,521 patients with a transvenous pacemaker were included in the study. Mean follow-up was 10 months.